Next Article in Journal
Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development
Next Article in Special Issue
Recent Advances in the Total Synthesis of Spirotryprostatin Alkaloids
Previous Article in Journal
The Effect of Ultrasound on the Extraction and Functionality of Proteins from Duckweed (Lemna minor)
Previous Article in Special Issue
Biological Evaluations, NMR Analyses, Molecular Modeling Studies, and Overview of the Synthesis of the Marine Natural Product (−)-Mucosin
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of a Non-Symmetrical Disorazole C1-Analogue and Its Biological Activity

1
Medicinal Chemistry and Chemical Biology Laboratory, School of Pharmacy, University of California San Francisco, 600 16th St., San Francisco, CA 94158, USA
2
Chemisches Institut, Otto-von-Guericke-Universität, Universitätsplatz 2, 39106 Magdeburg, Germany
3
Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstraße 7, 38124 Braunschweig, Germany
4
Institute of Microbiology, Technische Universität Braunschweig, Spielmannstraße 7, 38106 Braunschweig, Germany
*
Author to whom correspondence should be addressed.
Molecules 2024, 29(5), 1123; https://doi.org/10.3390/molecules29051123
Submission received: 8 February 2024 / Revised: 19 February 2024 / Accepted: 29 February 2024 / Published: 1 March 2024

Abstract

:
The synthesis of a novel disorazole C1 analogue is described, and its biological activity as a cytotoxic compound is reported. Based on our convergent and flexible route to the disorazole core, we wish to report a robust strategy to synthesize a non-symmetrical disorazole in which we couple one half of the molecule containing the naturally occurring oxazole heterocycle and the second half of the disorazole macrocycle containing a thiazole heterocycle. This resulted in a very unusual non-symmetrical disorazole C1 analogue containing two different heterocycles, and its biological activity was studied. This provided exciting information about SAR (structure-activity-relationship) for this highly potent class of antitumor compounds.

Graphical Abstract

1. Introduction

The disorazoles are a family of 39 macrolides isolated so far, showing macrolide ring sizes between 26 and 32 (Figure 1) [1,2,3]. They are secondary metabolites from the Myxobacterium Sorangium cellulosum (So ce12) and were isolated by the research groups of Höfle and Reichenbach in 1994 [4].
All these natural products show very potent antitumor activity due to inhibition of tubulin polymerization combined with a very powerful cytotoxicity up to picomolar activity against various human cancer cell lines [5,6]. This exciting biological profile generated a tremendous interest in the scientific community in both total synthesis and biology [7]. In addition, their enormous biological potency makes them very attractive in personalized medicine as potesntial payloads for antibody-drug conjugates (ADCs) in targeted cancer therapy [8].
We recently published a flexible and robust new route to synthesize (—)-disorazole C1, which involved, at the endgame, a coupling of the building blocks via Yamaguchi esterification and a final Yamaguchi macrolactonization [9].
The advantage of this powerful strategy to construct the disorazole core is that it offers high diversity in each building block before the desired coupling takes place and provides great opportunities to design a variety of disorazole analogues to study SAR (structure-activity relationships) [10].
Based on this strategy, we wish to show our efforts along these lines and report an efficient synthesis to construct a non-symmetrical disorazole C1 analogue with potent antitumor activity. Most of the published analogues of this highly active natural product family are based on symmetrical compounds, and to the best of our knowledge, only one non-symmetrical disorazole synthesis has been published in the past by K. C. Nicolaou [11].

2. Results

In a recent study, we focused on the structure-activity relationship of the disorazole C1 core by exchanging the oxazole ring with thiazole, and we studied the influence of chiral centers within the disorazole framework [10]. Employing the same strategy we successfully used in our total synthesis of disorazole C1, we have prepared an analogue with the oxazole ring replaced by a thiazole unit. To our surprise, this replacement resulted in an increase in IC50 values between 200- and 800-fold. Even more dramatic was the inversion of configuration at C(14)/C(14’) stereocenters, with a drop in activity of several thousand-fold [10].
Much less influence had the inversion of configuration at C(5)/C(5’) stereocenters, with a loss of activity of only between 40- and 160-fold [10].
Based on these findings, it would be of great interest to synthesize a kind of hybrid structure connecting one half of the C2-symmetric macrocycle containing the natural oxazole heterocycle and the other half containing a thiazole unit.
Our published strategy offers the possibility of synthesizing a large variety of disorazole analogues. In order to construct hybrid 16, one just has to construct the two halves 9 and 10. Fragment 10 can be used from the total synthesis of disorazole C1, and the thiazole fragment 9 can be used from the synthesis of bis-thiazole 17.
Alcohol 9 was esterified using the Yamaguchi protocol with acid 10 to obtain compound 11 at 81% as a single compound (Scheme 1). Mild deprotection of TES-protected compound 11 with CSA provided the desired alcohol 12, which was directly hydrolyzed with LiOH, providing the starting material 13 for the Yamaguchi macrolactonization. Macrocycle 14 was isolated in 58% yield as a single isomer, which was transferred to the required (E,Z,Z)-triene derivative 15 in 62% using the Boland hydrogenation protocol.
Very simple deprotection of the bis-MOM compound 15 with two drops of HBr at −15 °C in CH3CN provided the disorazole analogue 16 in 50% yield.
After completion of the synthesis of 16, the biological activity of the analogue was evaluated against several immortalized animal and human cancer cell lines and compared to the cytotoxicity of synthetic disorazole C1 and epothilone B as internal controls (Figure 2) [12,13].
Table 1 shows these results and demonstrates again the very high activity of disorazole C1 in the low sub-nanomolar range (between 0.11 and 0.6 ng/mL). Compound 16 is only one order of magnitude less active than the natural product 4, but several orders of magnitude more active than the bis-thiazole analogue 17.

3. Discussion

The hybrid disorazole 16 provides a very important piece of information to understand the biological activity of disorazoles because we can compare a series of analogues and can now offer a rationale to understand the activity differences and bring some light into the structure-activity relationship (SAR) of these fascinating molecules.
So far, only for disorazole Z, an X-ray exists to provide competitive data about the interaction of the molecule with the target protein tubulin [14,15]. Given the fact that more or less the same interactions take place with other disorazoles, only one half of disorazole C1 is involved in protein binding to tubulin, and therefore, this can explain the activity differences with our compounds.
Disorazole C1 is still the most active compound in our series, whereas bis-thiazole 17 showed around 200–800 fold less activity. However, hybrid 16 still retained most of the activity of the natural product 4, with an increased IC50 value of about a maximum of 10. This clearly demonstrates that the natural oxazole half of 16 preferentially binds to the protein, leaving the thiazole half outside of the close interaction with tubulin. In addition, it explains the quite large drop in activity of the bis-thiazole compound 17.

4. Materials and Methods

Solvents were dried by standard procedures and redistilled under an N2 atmosphere prior to use. All reactions were run under nitrogen, unless otherwise stated. For reactions that require heating, an oil bath was used as an external heat source. When the reactions were run at room temperature, a temperature of 22 °C ± 2 °C was implied. The products were purified by flash chromatography on Merck silica gel 60 (40–63 μm). POLYGRAM SIL G/UV254 prefabricated TLC plates with fluorescent indicators from Macherey-Nagel have been used for analytical thin layer chromatography (TLC). The separated substances were detected by irradiation with UV light with a wavelength of 254 nm, staining with vanillin or potassium permanganate reagent, and subsequent warming with a heat gun. Electrospray ionization (ESI) mass spectra were recorded on Waters Xevo G2-TOF spectrometers. 1H and 13C-NMR spectra were recorded on Bruker AVIII 400 and Bruker AVI 600 spectrometers (Supplementary Materials). Chemical shifts (δ) are reported in ppm, referencing the resonance signal of the residual undeuterated solvent for 1H- NMR and the deuterated solvent for 13C-NMR (1H-NMR = CDCl3: δ 7.26, CD3OD: δ 3.31; 13C-NMR = CDCl3: δ 77.16, CD3OD: δ 49.00). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, br = broad, m = multiplet, app = apparent), coupling constants (Hz), and integration. Optical rotations were recorded on Perkin-Elmer 341 and Anton Paar MCP150 polarimeters employing the solvent and concentration indicated and are reported in units of 10−1 (deg cm2 g−1).
11: NEt3 (90 µL, 0.648 mmol, 6 eq) and 2,4,6-trichlorobenzoyl chloride (68 µL, 0.432 mmol, 4 eq) were added to a solution of carboxylic acid 10 (91 mg, 0.162 mmol, 1.5 eq) in THF (5 mL), and the resulting turbid solution was stirred for 2 h at room temperature. Toluene (3 mL) was added, and then the mixture was added dropwise to a solution of alcohol 9 (50 mg, 0.108 mmol) and DMAP (79 mg, 0.648 mmol, 6 eq) in toluene (5 mL). The mixture was stirred for 16 h at room temperature and then quenched with a saturated aqueous NH4Cl solution (15 mL). The aqueous phase was extracted with EtOAc (3 × 10 mL). The organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (Et2O/pentane 2:1) to afford 11 (83 mg, 0.0813 mmol, 81%) as a slightly yellow oil. General Data: C55H80N2O12SSi; MW: 1021.39; TLC: Rf = 0.30 (pentane/Et2O 2:1); UV (+); Vanillin: black; [ α ] D 20 = +24.44 (c = 0.9, CHCl3).
1H-NMR (400 MHz, CD3OD): δ (ppm): 8.47 (s, 1H); 8.25 (s, 1H); 6.10–6.23 (m, 1H); 6.02–5.94 (m, 4H); 5.90–5.80 (m, 1H); 5.72–5.58 (m, 4H); 5.47–5.33 (m, 2H); 5.25 (app t, J = 6.6 Hz, 1H); 4.69–4.59 (m, 2H); 4.50–4.37 (m, 2H); 4.24–4.16 (m, 1H); 3.88 (s, 3H); 3.89–3.83 (m, 2H); 3.34 (s, 3H); 3.33 (s, 3H); 3.28 (s, 3H); 3.27 (s, 3H); 3.44–2.98 (m, 3H); 2.81–2.70 (m, 2H); 2.65–2.54 (m, 2H); 2.48–2.39 (m, 1H); 1.72 (ddd, J = 12.8, 6.6, 1.6 Hz, 6H); 0.984 (app t, J = 7.6 Hz, 9H); 1.01 (s, 3H); 0.96 (s, 3H); 0.94 (s, 3H); 0.87 (s, 3H); 0.64 (q, J = 7.7 Hz, 6H). 13C NMR (101 MHz, CD3OD): δ (ppm): 164.41, 164.38, 162.87, 162.22, 146.08, 143.59, 142.00, 141.81, 141.66, 136.61, 133.61, 133.16, 132.34, 129.19, 128.63, 128.51, 114.76, 114.57, 112.11, 110.81, 94.64, 94.52, 92.57, 88.92, 88.49, 82.75, 81.37, 80.08, 78.59, 77.90, 66.91, 61.53, 57.12, 57.07, 56.33, 55.97, 52.48, 44.22, 42.85, 35.50, 35.04, 34.65, 32.40, 19.73, 19.54, 18.05, 18.03, 15.45, 14.47, 7.52, 6.52. HRMS (ESI) m/z: [M+H]+ Calcd for C55H81N2O12SSi: 1021.5279; found: 1021.5275.
14: TES-protected alcohol 11 (80.3 mg, 0.0787 mmol) was dissolved in CH2Cl2/MeOH 1:1 (4 mL, 0.02 M) and cooled to 0 °C. CSA (3.7 mg, 0.0157 mmol, 0.2 eq) was added, and the mixture was stirred for 1 h at 0 °C under a normal atmosphere. Saturated aqueous NaHCO3 solution (5 mL) was added, and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 × 5 mL), and the combined organic extracts were dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was used in the next step without further purification. General Data: C49H66N2O12S; MW: 907.13; TLC: Rf = 0.30 (CH2Cl2/MeOH 50:1); UV (+); Vanillin: black; [ α ] D 20 = +40.4 (c = 0.5, CHCl3). HRMS (ESI) m/z: [M+H]+ Calcd for C49H67N2O12S: 907.4415; found: 907.4415. Deprotected alcohol 12 (71.3 mg, 0.0787 mmol) was dissolved in THF (2 mL) and LiOH (1 M in H2O, 0.236 mL, 0.236 mmol, 3 eq) was added. The mixture was stirred at room temperature for 16 h and neutralized with 1 M HCl (~1 mL). The aqueous phase was extracted with Et2O (3 × 3 mL), and the organic extracts were dried over Na2SO4, filtered, and concentrated in vacuo to give crude seco-acid 13, which was used for the next step without further purification. General Data: C48H64N2O12S; MW: 893.10; TLC: UV (+); Vanillin: black; [ α ] D 20 = +24.4 (c = 0.5, CHCl3). HRMS (ESI) m/z: [M+H]+ Calcd for C48H65N2O12S: 893.4258; found: 893.4261. NEt3 (219 μL, 1.57 mmol, 20 eq) and 2,4,6-trichlorobenzoyl chloride (123 μL, 0.787 mmol, 10 eq) were added at room temperature to a solution of crude 13 (66 mg, 0.0787 mmol) in THF (5 mL), and this turbid solution was stirred for 2 h at room temperature. Toluene (2 mL) was added, and the solution was added dropwise to a solution of DMAP (385 mg, 3.15 mmol, 40 eq) in toluene (40 mL). The mixture was stirred overnight at room temperature, and then quenched with saturated aqueous NH4Cl solution (10 mL), water (10 mL), and the aqueous phase was extracted with EtOAc (3 × 20 mL). The organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (hexane/EtOAc 2:1 to 1:1) to afford the macrocycle 14 (40 mg, 0.0457 mmol, 58% from 11) as a yellow wax. General Data: C48H62N2O11S; MW: 875.09; TLC: Rf = 0.50 (CH2Cl2/MeOH 50:1); UV (+); Vanillin: black; [ α ] D 20 = +160.40 (c = 0.5, CHCl3). 1H-NMR (400 MHz, CDCl3): δ (ppm): 8.05 (s, 1H); 7.98 (s, 1H); 6.03–5.89 (m, 4H); 5.84–5.71 (m, 2H); 5.70–5.57 (m, 3H); 5.52 (m, 1H); 5.46–5.27 (m, 4H); 4.65 (dd, J = 16.0, 6.5 Hz, 2H); 4.40 (dd, J = 16.2, 6.7 Hz, 2H); 4.17–4.07 (m, 2H); 3.75 (dt, J = 9.0, 3.4 Hz, 2H); 3.38 (s, 3H); 3.36 (s, 3H); 3.35 (s, 3H); 3.34 (s, 3H); 3.29 (m, 2H); 3.26–3.14 (m, 2H); 3.07–2.94 (m, 2H); 2.47–2.37 (m, 2H); 1.72 (m, 6H); 1.07 (s, 3H); 1.05 (s, 3H); 1.03 (s, 3H); 1.00 (s, 3H). 13C NMR (101 MHz, CDCl3): δ (ppm): 165.71, 161.83, 160.63, 160.62, 147.20, 147.27, 143.55, 140.76, 140.70, 140.33, 133.77, 132.01, 131.89, 127.39, 127.28, 114.51, 113.42, 112.21, 112.11, 93.83, 93.78, 91.08, 91.02, 87.98, 87.96, 81.64, 81.48, 80.35, 79.39, 77.36, 76.67, 57.07, 56.93, 56.19, 56.17, 41.69, 41.64, 39.07, 34.51, 31.73, 31.60, 20.04, 19.86, 19.69, 19.64, 18.10, 18.07. HRMS (ESI) m/z: [M+H]+ Calcd for C48H63N2O11S: 875.4330; found: 875.4332.
15: Nitrogen was bubbled for 15 min through a suspension of zinc dust (5.00 g, 45.88 mmol) in H2O (30 mL), and then Cu(OAc)·2H2O (500 mg, 2.5 mmol) was added at room temperature. After 15 min, AgNO3 (500 mg, 2.94 mmol) was added carefully. The mixture was stirred for 30 min at room temperature, filtered by suction, and finally washed with H2O (40 mL), MeOH (30 mL), acetone (30 mL), and Et2O (30 mL). This activated zinc solid was added to a solution of 14 (31.5 mg, 0.0360 mmol) in MeOH/H2O 1:1 (20 mL), nitrogen was once again bubbled through the suspension for 10 min, and then the flask was sealed. The mixture was stirred for 24 h at 50 °C, then filtered on a small pad of silica with MeOH washes. The filtrate was concentrated in vacuo and the residue was purified by flash chromatography (CH2Cl2/MeOH 70:1) to afford 15 (19 mg, 0.0216 mmol, 62%) as a colorless wax. General Data: C48H66N2O11S; MW: 879.12; TLC: Rf = 0.40 (CH2Cl2/MeOH 50:1); UV (+); Vanillin: dark green; [ α ] D 20 = −19.9 (c = 1.0, CHCl3). 1H-NMR (600 MHz, CDCl3): δ (ppm): 7.89 (s, 1H); 7.82 (s, 1H); 6.47–4.26 (m, 5H); 6.18 (dd, J = 19.7, 10.4 Hz, 1H); 6.95–6.83 (m, 2H); 5.67–5.58 (m, 3H); 5.57–5.47 (m, 3H); 5.43–5.36 (m, 2H); 5.31–5.25 (m, 2H); 4.68–4.63 (m, 2H); 4.43–4.36 (m, 2H); 4.16–4.08 (m, 2H); 3.72 (dd, J = 18.9, 8.9 Hz, 2H); 3.42–3.36 (m, 2H); 3.33 (s, 3H); 3.32 (s, 3H); 3.28 (s, 3H); 3.27 (s, 3H); 3.19–3.09 (m, 2H); 2.99 (dd, J = 14.0, 7.6 Hz, 1H); 2.81 (dd, J = 14.7, 8.1 Hz, 1H); 2.50–2.43 (m, 1H); 2.40–2.31 (m, 1H); 1.72 (ddd, J = 9.0, 5.3, 4.5 Hz, 6H); 1.03 (s, 3H); 1.01 (s, 3H); 0.98 (s, 3H); 0.94 (s, 3H). 13C NMR (151 MHz, CDCl3): δ (ppm): 166.53, 162.41, 160.75, 160.74, 147.20, 143.24, 133.53, 133.22, 132.99, 132.11, 132.05, 130.17, 129.75, 129.61, 129.43, 128.18, 128.10, 127.38, 127.22, 127.14, 126.70, 125.61, 125.52, 125.44, 93.62, 81.87, 81.69, 81.63, 81.11, 80.14, 77.57, 56.67, 56.58, 56.13, 56.11, 41.72, 41.69, 39.74, 35.14, 29.84, 28.39, 20.32, 20.16, 20.00, 19.90, 18.08, 18.06. HRMS (ESI) m/z: [M+H]+ Calcd for C48H67N2O11S: 879.4466; found 879.4461.
16: Compound 15 (17.5 mg, 19.91 μmol) was dissolved in acetonitrile (2 mL) and cooled to −15 °C. HBr (two drops, 48% in H2O) was added dropwise, and the mixture was stirred for 2 h 30 min at −15 °C. EtOAc (5 mL) was added, and the mixture was washed with saturated aqueous NaHCO3 solution (5 mL). The aqueous phase was extracted with EtOAc (3 × 5 mL), and the organic extracts were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (CH2Cl2/MeOH 50:1) to give thiazolyl-disorazole C1 (16) (7.9 mg, 9.95 μmol, 50%) as a colorless wax. General Data: C44H58N2O9S; MW: 791.01; TLC: Rf = 0.20 (CH2Cl2/MeOH 50:1); UV (+); Vanillin: dark green; [ α ] D 20 = −85.9 (C = 0.191 in MeOH). 1H-NMR (600 MHz, CD3OD): δ (ppm): 8.26 (s, 1H); 8.21 (s, 1H); 6.54–6.45 (m, 2H); 6.43–6.34 (m, 2H); 6.27 (dd, J = 21.4, 10.5 Hz, 2H); 5.93 (app t, J = 11.0 Hz, 1H); 5.83 (dd, J = 10.7, 5.9 Hz, 1H); 5.71–5.62 (m, 2H); 5.62–5.53 (m, 2H); 5.53–5.42 (m, 4H); 5.26 (app dt, J = 14.0, 2.7 Hz, 2H); 4.14 (dd, J = 13.7, 7.4 Hz, 2H); 3.86 (dd, J = 20.7, 8.1 Hz, 2H); 3.25 (s, 3H); 3.22 (s, 3H); 3.04–2.96 (m, 2H); 2.78 (dd, J = 15.5, 5.7 Hz, 2H); 2.72–2.62 (m, 2H); 2.48–2.39 (m, 2H); 1.70 (ddd, J = 11.8, 6.4, 1.3 Hz, 6H); 1.03 (s, 3H); 1.01 (s, 3H); 0.98 (s, 3H); 0.95 (s, 3H). 13C NMR (151 MHz, CD3OD): δ (ppm): 168.90, 164.27, 162.25, 147.55, 145.76, 134.42, 134.10, 133.80, 131.70, 131.66, 130.85, 130.60, 130.18, 129.88, 129.67, 129.62, 129.43, 129.13, 129.03, 127.32, 127.15, 126.77, 126.55, 81.66, 80.77, 79.13, 78.78, 77.91, 77.83, 56.89, 56.78, 42.81, 42.75, 40.42, 35.96, 29.28, 29.09, 19.46, 19.42, 19.31, 18.04. HRMS (ESI) m/z: [M+H]+ Calcd for C44H59N2O9S: 791.3941; found 791.3938.

5. Conclusions

The disorazoles are a fascinating group of natural products that attracted both the synthetic chemistry community and biologists. Within the last decade, quite a few research groups have reported new total synthesis efforts and strategies to synthesize these attractive molecules. In addition, several SAR studies have been reported to shed some light on the biology of these interesting compounds. Our results provide some more rationale for these findings for the future because still no in vivo data is reported about the therapeutic usefulness of these highly active molecules. Based on the outstanding cytotoxicity of the compounds, it is still very reasonable that they could be powerful payloads for ADCs.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules29051123/s1, 1H- and 13C-NMR spectra of synthesized compounds.

Author Contributions

Conceptualization, L.L. and D.S.; methodology, L.L.; investigation, S.R.; writing—original draft preparation, D.S.; writing—review and editing, visualization, O.S.; supervision, D.S. and M.S. All authors have read and agreed to the published version of the manuscript.

Funding

Luca Lizzadro thanks the state of Saxony-Anhalt for a fellowship.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article and Supplementary Materials.

Acknowledgments

The authors thank Wera Collisi for conduction of the bioassays.

Conflicts of Interest

The authors declare no conflict of interests.

References

  1. Jahresbericht GBF 2001. Available online: https://www.helmholtz-hzi.de/fileadmin/user_upload/Infothek/Ueber_das_HZI/Jahresberichte/Ergebnisberichte/Annual_Report_2001.pdf (accessed on 7 February 2024).
  2. Irschik, H.; Jansen, R.; Gerth, K.; Höfle, G.; Reichenbach, H. Disorazole A1, an Efficient Inhibitor of Eukariotic Organisms Isolated from Myxobacteria. J. Antibiot. 1995, 48, 31–35. [Google Scholar] [CrossRef] [PubMed]
  3. Weissman, K.J.; Mueller, R. Myxobacterial secondary metabolites: Bioactivities and modes-of-action. Nat. Prod. Rep. 2010, 27, 1276–1295. [Google Scholar] [CrossRef] [PubMed]
  4. Jansen, R.; Irschik, H.; Reichenbach, H.; Wray, V.; Höfle, G. Disorazoles, Highly Cytotoxyc Metabolites from the Sorangicin–Producing Bacterium Sorangium cellulosum. Liebigs Ann. Chem. 1994, 1994, 759–773. [Google Scholar] [CrossRef]
  5. Elnakady, Y.A.; Sasse, F.; Lünsdorf, H.; Reichenbach, H. Disorazol A1, a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells. Biochem. Pharmacol. 2004, 67, 927–935. [Google Scholar] [CrossRef] [PubMed]
  6. Gao, Y.; Birkelbach, J.; Fu, C.; Herrmann, J.; Irschik, H.; Morgenstern, B.; Hirschfelder, K.; Li, R.; Zhang, Y.; Jansen, R.; et al. The Disorazole Z Family of Highly Potent Anticancer Natural Products from Sorangium cellulosum: Bioactivity, Biosynthesis, and Heterologous Expression. Microbiol. Spectr. 2023, 11, e00730-23. [Google Scholar] [CrossRef] [PubMed]
  7. Bold, C.P.; Altmann, K.-H. The Chemistry of Disorazoles and Structure-Activity Relationships: An Update. Tetrahedron 2024, in press. [Google Scholar] [CrossRef]
  8. Perez, H.L.; Cardaerelli, P.M.; Deshpande, S.; Gangwar, S.; Schroeder, G.M.; Vite, G.D.; Borzilleri, R.M. Antibody-drug conjugates: Current status and future directions. Drug Discov. Today 2014, 19, 869–881. [Google Scholar] [CrossRef]
  9. Lizzadro, L.; Spieß, O.; Schinzer, D. Total Synthesis of (−)-Disorazole C1. Org. Lett. 2021, 23, 4543–4547. [Google Scholar] [CrossRef] [PubMed]
  10. Lizzadro, L.; Spieß, O.; Collisi, W.; Stadler, L.; Schinzer, D. Extending the Struture-Activity Relationship of Disorazole C1: Exchanging the Oxazole Ring by Thiazole and Influence of Chiral Centers within Disorazole Core on Cytotoxicity. ChemBioChem 2022, 23, e202200458. [Google Scholar] [CrossRef]
  11. Nicolaou, K.C.; Bellavance, G.; Buchman, M.; Pulikuri, K.K. Total Synthesis of Disorazoles A1 and B1 and full Structural Elucidation of Disorazole B1. J. Am. Chem. Soc. 2017, 139, 15636–15639. [Google Scholar] [CrossRef] [PubMed]
  12. Shao, L.; Marin-Felix, Y.; Surup, F.; Stchigel, A.M.; Stadler, M. Seven New Cytotoxic and Antimicrobial Xanthoquinodins from Jugulospora vestita. J. Fungi 2020, 6, 188. [Google Scholar] [CrossRef] [PubMed]
  13. Becker, K.; Wessel, A.-C.; Luangsa-ard, J.J.; Stadler, M. Viridistratins A-C, Antimicrobial and Cytotoxic Benzo[j]fluoranthenes from Stromata of Annulohypoxylon viridistratum (Hypoxylaceae, Ascomycota). Biomolecules 2020, 10, 805–816. [Google Scholar] [CrossRef] [PubMed]
  14. Menchon, G.; Prota, A.E.; Lucena-Agell, D.; Bucher, P.; Jansen, R.; Irschik, H.; Müller, R.; Paterson, I.; Díaz, J.F.; Altmann, K.-H.; et al. A fluorescense anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. Nat. Commun. 2018, 9, 2106. [Google Scholar] [CrossRef] [PubMed]
  15. Bold, C.P.; Lucena-Agnel, D.; Olive, M.A.; Diaz, J.F.; Altmann, K. Synthesis and Biological Evaluation of C(13)/C(13’)-Bis(desmethyl)disorazole Z. Angew. Chem. Int. Ed. 2023, 62, e202212190. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Selected members of the disorazole family. The percentages correspond to the relative abundance from the initial isolation from Sorangium cellulosum, So ce12.
Figure 1. Selected members of the disorazole family. The percentages correspond to the relative abundance from the initial isolation from Sorangium cellulosum, So ce12.
Molecules 29 01123 g001
Scheme 1. Reagents and conditions: (a) 2,4,6-trichlorobenzoyl chloride, NEt3, DMAP, THF/toluene, rt, 18 h, 81%; (b) CSA, DCM/MeOH, 0 °C, 1 h; (c) LiOH, THF/H2O, rt, 16 h; (d) 2,4,6-trichlorobenzoyl chloride, NEt3, DMAP, THF/toluene, rt 18 h, 58% from 10; (e) activated zinc, MeOH/H2O, 50 °C, 24 h, 62%; (f) HBr, ACN, −15 °C, 2 h 30 min, 50%. NEt3 = triethylamine; DMAP = 4-dimethylaminopyridine; CSA = camphorsulfonic acid; LiOH = lithium hydroxide; HBr = hydrogen bromide; ACN = acetonitrile.
Scheme 1. Reagents and conditions: (a) 2,4,6-trichlorobenzoyl chloride, NEt3, DMAP, THF/toluene, rt, 18 h, 81%; (b) CSA, DCM/MeOH, 0 °C, 1 h; (c) LiOH, THF/H2O, rt, 16 h; (d) 2,4,6-trichlorobenzoyl chloride, NEt3, DMAP, THF/toluene, rt 18 h, 58% from 10; (e) activated zinc, MeOH/H2O, 50 °C, 24 h, 62%; (f) HBr, ACN, −15 °C, 2 h 30 min, 50%. NEt3 = triethylamine; DMAP = 4-dimethylaminopyridine; CSA = camphorsulfonic acid; LiOH = lithium hydroxide; HBr = hydrogen bromide; ACN = acetonitrile.
Molecules 29 01123 sch001
Figure 2. Disorazole C1 and analogues tested.
Figure 2. Disorazole C1 and analogues tested.
Molecules 29 01123 g002
Table 1. Biological activities of Disorazole C1 and thio analogues. Epothilone B was used as internal standard.
Table 1. Biological activities of Disorazole C1 and thio analogues. Epothilone B was used as internal standard.
Cell Line
L929KB3.1A431A549PC-3MCF-7
CompoundIC50 (ng/mL)
Epothilone B0.240.0170.0260.0340.0480.015
Disorazole C1 40.250.230.320.600,110.28
Analogue 162.10.940.941.61.70.75
Analogue 1718085828612091
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lizzadro, L.; Spieß, O.; Reinecke, S.; Stadler, M.; Schinzer, D. Synthesis of a Non-Symmetrical Disorazole C1-Analogue and Its Biological Activity. Molecules 2024, 29, 1123. https://doi.org/10.3390/molecules29051123

AMA Style

Lizzadro L, Spieß O, Reinecke S, Stadler M, Schinzer D. Synthesis of a Non-Symmetrical Disorazole C1-Analogue and Its Biological Activity. Molecules. 2024; 29(5):1123. https://doi.org/10.3390/molecules29051123

Chicago/Turabian Style

Lizzadro, Luca, Oliver Spieß, Silke Reinecke, Marc Stadler, and Dieter Schinzer. 2024. "Synthesis of a Non-Symmetrical Disorazole C1-Analogue and Its Biological Activity" Molecules 29, no. 5: 1123. https://doi.org/10.3390/molecules29051123

APA Style

Lizzadro, L., Spieß, O., Reinecke, S., Stadler, M., & Schinzer, D. (2024). Synthesis of a Non-Symmetrical Disorazole C1-Analogue and Its Biological Activity. Molecules, 29(5), 1123. https://doi.org/10.3390/molecules29051123

Article Metrics

Back to TopTop